In today’s session bluebird bio Inc (BLUE) recorded an unusually high (390) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious BLUE decrease. With 390 contracts traded and 3314 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: BLUE161118P00040000 closed last at: $2.8 or 166.7% up. About 278,365 shares traded hands. bluebird bio Inc (NASDAQ:BLUE) has declined 6.81% since April 5, 2016 and is downtrending. It has underperformed by 8.77% the S&P500.
bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage
Out of 13 analysts covering bluebird bio (NASDAQ:BLUE), 10 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 77% are positive. $244 is the highest target while $14 is the lowest. The $113 average target is 151.39% above today’s ($44.95) stock price. bluebird bio has been the topic of 28 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm earned “Sell” rating on Friday, October 14 by Cantor Fitzgerald. The company was downgraded on Monday, December 7 by Bank of America. The rating was initiated by Wells Fargo on Friday, December 4 with “Outperform”. The stock of bluebird bio Inc (NASDAQ:BLUE) has “Buy” rating given on Wednesday, November 18 by Goldman Sachs. On Wednesday, February 3 the stock rating was initiated by Leerink Swann with “Outperform”. On Monday, October 5 the stock rating was upgraded by Morgan Stanley to “Overweight”. The firm has “Overweight” rating by JP Morgan given on Monday, August 24. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, December 7. The stock has “Buy” rating given by Roth Capital on Thursday, September 22. Goldman Sachs maintained the shares of BLUE in a report on Thursday, September 15 with “Buy” rating.
According to Zacks Investment Research, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1 in Q2 2016. Its down 0.34, from 1.34 in 2016Q1. The ratio fall, as 29 funds sold all bluebird bio Inc shares owned while 52 reduced positions. 20 funds bought stakes while 61 increased positions. They now own 42.29 million shares or 3.30% more from 40.94 million shares in 2016Q1.
Paradigm Asset Management Limited Liability Corp holds 0% or 350 shares in its portfolio. Alps Advsr accumulated 51,898 shares or 0.02% of the stock. Ameriprise holds 0% or 79,002 shares in its portfolio. Quantbot Tech L P has 2,848 shares for 0.01% of their US portfolio. Rs Management Communication Ltd owns 575,093 shares or 0.26% of their US portfolio. Moreover, Amalgamated National Bank has 0.01% invested in bluebird bio Inc (NASDAQ:BLUE) for 3,995 shares. Alliancebernstein Limited Partnership, a New York-based fund reported 56,920 shares. Pnc Financial Services Group Inc has 1,150 shares for 0% of their US portfolio. Sei Investments has 0% invested in the company for 1,217 shares. Portolan Mngmt has 0.23% invested in the company for 37,090 shares. Qvt L P has invested 0.18% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Tiaa Cref Mgmt Ltd Liability Corporation holds 151,224 shares or 0.01% of its portfolio. Jpmorgan Chase And Communication last reported 0% of its portfolio in the stock. The Massachusetts-based Eventide Asset Mgmt Ltd Com has invested 1.43% in bluebird bio Inc (NASDAQ:BLUE). Northern Tru accumulated 0.01% or 404,141 shares.
bluebird bio, Inc. is a biotechnology company. The company has a market cap of $1.60 billion. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. It currently has negative earnings. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
BLUE Company Profile
bluebird bio, Inc., incorporated on April 16, 1992, is a biotechnology company. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. With its lentiviral gene therapies, T cell immunotherapy expertise and gene editing capabilities, it offers an integrated product platform with application in severe genetic and rare diseases, and in oncology. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. The Company’s oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. The Company’s oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
More notable recent bluebird bio Inc (NASDAQ:BLUE) news were published by: Fool.com which released: “Why bluebird bio Inc. Got Knocked Down Today” on November 03, 2016, also Fool.com with their article: “Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc.” published on October 25, 2016, Fool.com published: “Why Shares of bluebird bio Inc Took a Dive Today” on October 14, 2016. More interesting news about bluebird bio Inc (NASDAQ:BLUE) were released by: Fool.com and their article: “Why bluebird bio, Inc. Stock Soared 37.4% in September” published on October 11, 2016 as well as Businesswire.com‘s news article titled: “bluebird bio Reports Third Quarter 2016 Financial Results and Recent …” with publication date: November 02, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.